Lista de obras - Michela Rondoni - Dominio Público Uruguay

A rare case of Hemoglobin Leiden interfering with the DIFF channel of Sysmex XE-2100

artículo científico publicado en 2015

Advanced mast cell disease: an Italian Hematological Multicenter experience

artículo científico publicado en 2008

Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia

artículo científico publicado en 2006

Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia

artículo científico publicado en 2005

Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation

artículo científico publicado en 2004

Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts

artículo científico publicado en 2003

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias

artículo científico publicado en 2015

Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients

artículo científico publicado en 2016

Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.

artículo científico publicado en 2010

Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature

artículo científico publicado en 2003

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

artículo científico publicado en 2004

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

artículo científico publicado en 2004

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

artículo científico publicado en 2004

Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia

scientific article published on 01 May 2004

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

artículo científico publicado en 2005

Imatinib mesylate in the treatment of hematologic malignancies

artículo científico publicado en 2007

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study

artículo científico publicado en 2007

Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.

artículo científico publicado en 2009

Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.

artículo científico publicado en 2002

Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients

scientific article published on 14 February 2008

Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.

artículo científico publicado en 2003

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

artículo científico publicado en 2007

Mast cell leukemia: a report of ten cases

artículo científico publicado en 2008

Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely.

artículo científico publicado en 2004

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

artículo científico publicado en 2005

PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment

artículo científico publicado en 2007

Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia

artículo científico publicado en 2006

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

artículo científico publicado en 2003

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

artículo científico publicado en 2007

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

article by Simona Soverini et al published March 2007 in Lancet Oncology Commission

Serendipitous detection of Hemoglobin G-Ferrara variant with Sysmex DIFF channel

artículo científico publicado en 2015

Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant).

artículo científico publicado en 2015

Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission

artículo científico publicado en 2004

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients

artículo científico publicado en 2004

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

artículo científico publicado en 2007

Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia

scientific article published on 01 February 2010

Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.

artículo científico publicado en 2010

WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.

artículo científico publicado en 2007

Lista de obras de Michela Rondoni

A rare case of Hemoglobin Leiden interfering with the DIFF channel of Sysmex XE-2100

Advanced mast cell disease: an Italian Hematological Multicenter experience

Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia

Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia

Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation

Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias

Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients

Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.

Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

Imatinib mesylate in the treatment of hematologic malignancies

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study

Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.

Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.

Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients

Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

Mast cell leukemia: a report of ten cases

Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely.

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment

Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

Serendipitous detection of Hemoglobin G-Ferrara variant with Sysmex DIFF channel

Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant).

Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia

Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.

WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.